By Colin Kellaher
Allakos shares collapsed on Monday after the clinical-stage biotechnology company threw in the towel on its AK006 product candidate and said it would slash its workforce by 75%.
Shares of Allakos were recently down 77% to 27 cents, changing hands at their lowest level since the San Carlos, Calif., company went public in 2018.
Allakos said it is ending further development of AK006, its most advanced product candidate, after the drug didn't show therapeutic activity in a Phase 1 study in the skin condition chronic spontaneous urticaria.
Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a market capitalization of around $24 million after the steep drop in its share price.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 27, 2025 10:23 ET (15:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。